Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterial antibodies - Sorrento Therapeutics

Next Previous
Drug Profile

Research programme: antibacterial antibodies - Sorrento Therapeutics

Alternative Names: Anti-AIP mAbs; Anti-API1 mAb; Anti-API2 mAbs; Anti-MRSA antibodies - Sorrento Therapeutics; STI 001 program - Sorrento; STI-C0205; STI-C020X

Latest Information Update: 23 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sorrento Therapeutics
  • Developer Montana State University; Ohio State University; Sorrento Therapeutics
  • Class Antibodies; Bispecific antibodies; Monoclonal antibodies; Vaccines
  • Mechanism of Action Immunostimulants; Peptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Clostridium difficile infections; Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections

Most Recent Events

  • 23 Feb 2023 Discontinued - Preclinical for Methicillin-resistant Staphylococcus aureus infections in USA (Parenteral)
  • 23 Feb 2023 Discontinued - Preclinical for Pseudomonal infections in USA (Parenteral)
  • 28 Aug 2018 No recent reports of development identified for preclinical development in Pseudomonal-infections in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top